© 2002 by European Society of Cardiology
Copyright © 2002, European Society of Cardiology
Impact of HMG CoA reductase inhibition on small GTPases in the heart
Medizinische Klinik und Poliklinik der Universität des Saarlandes, Innere Medizin III, 66421 Homburg/Saar, Germany
ulrich{at}laufs.com
* Corresponding author. Tel.: +49-6841-162-3436; fax: +49-6841-162-3637
Objective: Members of the Rho GTPase family, Rac1 and RhoA have been suggested to be mediators of cardiac hypertrophy in mice. Rho proteins are posttranslationally isoprenylated. In addition to cholesterol-lowering, statins inhibit the isoprenylation of small G proteins. Therefore, it was tested if these drugs inhibit Rac1 and RhoA activity in cardiomyocytes and, thereby, prevent angiotensin II-mediated expression of atrial natriuretic factor (ANF) and myosin light chain (MLC)-2 in the heart. Methods and results: Western and Northern analysis of rat neonatal cardiomyocytes and H9C2 cells showed inhibition of basal and angiotensin-stimulated Rac1 expression, membrane-translocation and activity after statin treatment. Similarly, basal and stimulated RhoA membrane expression was inhibited. Statins concentration- and time-dependently downregulated basal as well as angiotensin-induced expression of ANF by 86±2.3% and 89±1.7%, as well as MLC-2 by 75±4.1% and 84±6%, respectively. Direct inhibition of Rac GTPase by overexpression of the dominant negative mutant RacN17 or by Clostridium sordellii lethal toxin in rat H9C2 cells inhibited ANF expression by 70±4.9% and 78±10%, respectively. Inhibition of RhoA by Clostridium botulinum C3 transferase or the dominant negative mutant RhoN19 reduced ANF mRNA by 19±11% and 23±8%, respectively. To test these findings in vivo, spontaneously hypertensive rats were treated with atorvastatin, leading to a decrease in cardiac Rac1 and RhoA activity as determined by [35S]-GTP
S-binding assays by 61±16% and 72±24%, and downregulation of MLC-2 as well as ANF mRNA expression by 31±16% and 80±24%, respectively. Conclusions: (1) Statins downregulate the activity of small G proteins in cardiomyocytes in culture as well as in vivo. (2) Inhibition of Rac1 and RhoA by statins reduces myocardial expression of ANF and MLC-2. (3) Targeting myocardial Rho GTPases by statins may be a novel treatment strategy to prevent cardiac hypertrophy.
KEYWORDS Myocytes; G-proteins; Gene expression; Lipid metabolism; Hypertrophy
1 Ulrich Laufs and Heiko Kilter contributed equally to this study.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Takuwa, S.-I. Ohkura, S.-I. Takashima, K. Ohtani, Y. Okamoto, T. Tanaka, K. Hirano, S. Usui, F. Wang, W. Du, et al. S1P3-mediated cardiac fibrosis in sphingosine kinase 1 transgenic mice involves reactive oxygen species Cardiovasc Res, October 6, 2009; (2009) cvp312v2. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. G. DeMarco, J. Habibi, A. T. Whaley-Connell, R. I. Schneider, J. R. Sowers, B. T. Andresen, A. A. Gutweiler, L. Ma, M. S. Johnson, C. M. Ferrario, et al. Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat Am J Physiol Heart Circ Physiol, September 1, 2009; 297(3): H1128 - H1139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Mallinson, D. Constantin-Teodosiu, J. Sidaway, F. R. Westwood, and P. L. Greenhaff Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy J. Physiol., January 1, 2009; 587(1): 219 - 230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Stuck, M. Lenski, M. Bohm, and U. Laufs Metabolic Switch and Hypertrophy of Cardiomyocytes following Treatment with Angiotensin II Are Prevented by AMP-activated Protein Kinase J. Biol. Chem., November 21, 2008; 283(47): 32562 - 32569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Adam, H.-R. Neuberger, M. Bohm, and U. Laufs Prevention of Atrial Fibrillation With 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Circulation, September 16, 2008; 118(12): 1285 - 1293. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ramasubbu, J. Estep, D. L. White, A. Deswal, and D. L. Mann Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J. Am. Coll. Cardiol., January 29, 2008; 51(4): 415 - 426. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yagi, K.-i. Aihara, Y. Ikeda, Y. Sumitomo, S. Yoshida, T. Ise, T. Iwase, K. Ishikawa, H. Azuma, M. Akaike, et al. Pitavastatin, an HMG-CoA Reductase Inhibitor, Exerts eNOS-Independent Protective Actions Against Angiotensin II Induced Cardiovascular Remodeling and Renal Insufficiency Circ. Res., January 4, 2008; 102(1): 68 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Shang, S. Sanyal, A. E. Pfahnl, Z. Jiao, J. Allen, H. Liu, and S. C. Dudley Jr. NF-{kappa}B-dependent transcriptional regulation of the cardiac scn5a sodium channel by angiotensin II Am J Physiol Cell Physiol, January 1, 2008; 294(1): C372 - C379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Zaca, S. Rastogi, M. Imai, M. Wang, V. G. Sharov, A. Jiang, S. Goldstein, and H. N. Sabbah Chronic Monotherapy With Rosuvastatin Prevents Progressive Left Ventricular Dysfunction and Remodeling in Dogs With Heart Failure J. Am. Coll. Cardiol., August 7, 2007; 50(6): 551 - 557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ruperez, R. Rodrigues-Diez, L. M. Blanco-Colio, E. Sanchez-Lopez, J. Rodriguez-Vita, V. Esteban, G. Carvajal, J. J. Plaza, J. Egido, and M. Ruiz-Ortega HMG-CoA Reductase Inhibitors Decrease Angiotensin II-Induced Vascular Fibrosis: Role of RhoA/ROCK and MAPK Pathways Hypertension, August 1, 2007; 50(2): 377 - 383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Adam, G. Frost, F. Custodis, M. A. Sussman, H.-J. Schafers, M. Bohm, and U. Laufs Role of Rac1 GTPase Activation in Atrial Fibrillation J. Am. Coll. Cardiol., July 24, 2007; 50(4): 359 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L.M. Peters and M. C. Michel The RhoA/Rho kinase pathway in the myocardium Cardiovasc Res, July 1, 2007; 75(1): 3 - 4. [Full Text] [PDF]
|
|
|
|
|
|
A. Bulhak, J. Roy, U. Hedin, P.-O. Sjoquist, and J. Pernow Cardioprotective effect of rosuvastatin in vivo is dependent on inhibition of geranylgeranyl pyrophosphate and altered RhoA membrane translocation Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H3158 - H3163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Takeda, M. Kondo, S. Ito, Y. Ito, K. Shimokata, and H. Kume Role of RhoA Inactivation in Reduced Cell Proliferation of Human Airway Smooth Muscle by Simvastatin Am. J. Respir. Cell Mol. Biol., December 1, 2006; 35(6): 722 - 729. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-M. Lee, M.-S. Lin, T.-F. Chou, and N.-C. Chang Additive effects of combined blockade of AT1 receptor and HMG-CoA reductase on left ventricular remodeling in infarcted rats Am J Physiol Heart Circ Physiol, September 1, 2006; 291(3): H1281 - H1289. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ushio-Fukai Redox signaling in angiogenesis: Role of NADPH oxidase Cardiovasc Res, July 15, 2006; 71(2): 226 - 235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Custodis, M. Eberl, H. Kilter, M. Bohm, and U. Laufs Association of RhoGDI{alpha} with Rac1 GTPase mediates free radical production during myocardial hypertrophy Cardiovasc Res, July 15, 2006; 71(2): 342 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Satoh, H. Ogita, K. Takeshita, Y. Mukai, D. J. Kwiatkowski, and J. K. Liao Requirement of Rac1 in the development of cardiac hypertrophy PNAS, May 9, 2006; 103(19): 7432 - 7437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Brown, D. P. Del Re, and M. A. Sussman The Rac and Rho Hall of Fame: A Decade of Hypertrophic Signaling Hits Circ. Res., March 31, 2006; 98(6): 730 - 742. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ichihara, A. Noda, K. Nagata, K. Obata, J. Xu, G. Ichihara, S. Oikawa, S. Kawanishi, Y. Yamada, and M. Yokota Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure Cardiovasc Res, February 15, 2006; 69(3): 726 - 735. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Cordle, J. Koenigsknecht-Talboo, B. Wilkinson, A. Limpert, and G. Landreth Mechanisms of Statin-mediated Inhibition of Small G-protein Function J. Biol. Chem., October 7, 2005; 280(40): 34202 - 34209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D.M. Engelmann and J. H. Svendsen Inflammation in the genesis and perpetuation of atrial fibrillation Eur. Heart J., October 2, 2005; 26(20): 2083 - 2092. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Song, P.-F. Deng, S. S. Stinnett, D. L. Epstein, and P. V. Rao Effects of Cholesterol-Lowering Statins on the Aqueous Humor Outflow Pathway Invest. Ophthalmol. Vis. Sci., July 1, 2005; 46(7): 2424 - 2432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-M. Lee, M.-S. Lin, T.-F. Chou, C.-H. Tsai, and N.-C. Chang Effect of pravastatin on development of left ventricular hypertrophy in spontaneously hypertensive rats Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H220 - H227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Kass Ventricular Arterial Stiffening: Integrating the Pathophysiology Hypertension, July 1, 2005; 46(1): 185 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Madonna, P. Di Napoli, M. Massaro, A. Grilli, M. Felaco, A. De Caterina, D. Tang, R. De Caterina, and Y.-J. Geng Simvastatin Attenuates Expression of Cytokine-inducible Nitric-oxide Synthase in Embryonic Cardiac Myoblasts J. Biol. Chem., April 8, 2005; 280(14): 13503 - 13511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-M. Lee, M.-S. Lin, T.-F. Chou, and N.-C. Chang Effect of simvastatin on left ventricular mass in hypercholesterolemic rabbits Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1352 - H1358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Wainwright Statins-is there no end to their usefulness? Cardiovasc Res, February 1, 2005; 65(2): 296 - 298. [Full Text] [PDF]
|
|
|
|
|
|
G. Nickenig Should Angiotensin II Receptor Blockers and Statins Be Combined? Circulation, August 24, 2004; 110(8): 1013 - 1020. [Full Text] [PDF]
|
|
|
|
|
|
M. Campbell, W. E. Allen, C. Sawyer, B. Vanhaesebroeck, and E. R. Trimble Glucose-Potentiated Chemotaxis in Human Vascular Smooth Muscle Is Dependent on Cross-Talk Between the PI3K and MAPK Signaling Pathways Circ. Res., August 20, 2004; 95(4): 380 - 388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Jacobson, S. M. Dudek, K. G. Birukov, S. Q. Ye, D. N. Grigoryev, R. E. Girgis, and J. G. N. Garcia Cytoskeletal Activation and Altered Gene Expression in Endothelial Barrier Regulation by Simvastatin Am. J. Respir. Cell Mol. Biol., May 1, 2004; 30(5): 662 - 670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Li, R. Luo, A. Kowluru, and G. Li Novel regulation by Rac1 of glucose- and forskolin-induced insulin secretion in INS-1 {beta}-cells Am J Physiol Endocrinol Metab, May 1, 2004; 286(5): E818 - E827. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Frey, H. A. Katus, E. N. Olson, and J. A. Hill Hypertrophy of the Heart: A New Therapeutic Target? Circulation, April 6, 2004; 109(13): 1580 - 1589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kumagai, H. Nakashima, and K. Saku The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model Cardiovasc Res, April 1, 2004; 62(1): 105 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. E. Porter, N. A. Turner, D. J. O'Regan, A. J. Balmforth, and S. G. Ball Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA Cardiovasc Res, March 1, 2004; 61(4): 745 - 755. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Varela and J. L. Garvin Acute and Chronic Regulation of Thick Ascending Limb Endothelial Nitric Oxide Synthase by Statins J. Am. Soc. Nephrol., February 1, 2004; 15(2): 269 - 275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Gregg, F. M. Rauscher, and P. J. Goldschmidt-Clermont Rac regulates cardiovascular superoxide through diverse molecular interactions: more than a binary GTP switch Am J Physiol Cell Physiol, October 1, 2003; 285(4): C723 - C734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Maack, T. Kartes, H. Kilter, H.-J. Schafers, G. Nickenig, M. Bohm, and U. Laufs Oxygen Free Radical Release in Human Failing Myocardium Is Associated With Increased Activity of Rac1-GTPase and Represents a Target for Statin Treatment Circulation, September 30, 2003; 108(13): 1567 - 1574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Pierini, R. J. Eddy, M. Fuortes, S. Seveau, C. Casulo, and F. R. Maxfield Membrane Lipid Organization Is Critical for Human Neutrophil Polarization J. Biol. Chem., March 14, 2003; 278(12): 10831 - 10841. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Laufs, O. Adam, K. Strehlow, S. Wassmann, C. Konkol, K. Laufs, W. Schmidt, M. Bohm, and G. Nickenig Down-regulation of Rac-1 GTPase by Estrogen J. Biol. Chem., February 14, 2003; 278(8): 5956 - 5962. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.O Bonetti, L.O Lerman, C Napoli, and A Lerman Statin effects beyond lipid lowering--are they clinically relevant? Eur. Heart J., February 1, 2003; 24(3): 225 - 248. [Full Text] [PDF]
|
|